Comparative Pharmacology
Head-to-head clinical analysis: HISPRIL versus LIVOSTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISPRIL versus LIVOSTIN.
HISPRIL vs LIVOSTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISPRIL (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and afterload.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
10 mg orally once daily, increased to 20 mg once daily after 2-4 weeks if needed.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
None Documented
None Documented
The terminal elimination half-life of HISPRIL is approximately 12-15 hours in patients with normal renal function, supporting twice-daily dosing. In moderate to severe renal impairment (CrCl <30 mL/min), half-life is prolonged up to 30-40 hours, necessitating dose interval adjustment.
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
HISPRIL is predominantly excreted renally, with approximately 60-70% of an administered dose recovered unchanged in urine over 48 hours. Hepatic metabolism accounts for <10% of elimination, and fecal excretion contributes <5%.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Category C
Category C
Antihistamine
Antihistamine